{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:02:31Z","timestamp":1772524951949,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Union's Horizon 2020 Research and Innovation program, Marie Sk\u0142odowska-Curie Action","award":["No 778051"],"award-info":[{"award-number":["No 778051"]}]},{"name":"European Union's Horizon 2020 Research and Innovation program, Marie Sk\u0142odowska-Curie Action","award":["No 778051"],"award-info":[{"award-number":["No 778051"]}]},{"name":"Ministry of Science and Higher Education of Poland","award":["No 3899\/H2020\/2018\/2"],"award-info":[{"award-number":["No 3899\/H2020\/2018\/2"]}]},{"name":"Ministry of Science and Higher Education of Poland","award":["No 3899\/H2020\/2018\/2"],"award-info":[{"award-number":["No 3899\/H2020\/2018\/2"]}]},{"name":"NIH\/NCI","award":["R01 CA251438"],"award-info":[{"award-number":["R01 CA251438"]}]},{"name":"NIH\/NCI","award":["R01 CA269513"],"award-info":[{"award-number":["R01 CA269513"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-024-03469-0","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:02:12Z","timestamp":1723474932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells"],"prefix":"10.1186","volume":"24","author":[{"given":"Aleksandra","family":"Romaniuk-Drapala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Skupin-Mrugalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Garbuzenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Hatefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Minko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"issue":"1","key":"3469_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3469_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.critrevonc.2010.07.004","volume":"79","author":"K Pliarchopoulou","year":"2011","unstructured":"Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol. 2011;79(1):17\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3469_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9\u201332.","journal-title":"Cancer Biol Med"},{"key":"3469_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijerph18073430","volume":"18","author":"M Kozlowski","year":"2021","unstructured":"Kozlowski M, Nowak K, Cymbaluk-Ploska A. Long-term follow-up of a female patient treated with olaparib-hope for a long life without relapse? Int J Environ Res Public Health. 2021;18:7.","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"3469_CR5","volume":"14","author":"UM Zamwar","year":"2022","unstructured":"Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022;14(10): e30561.","journal-title":"Cureus"},{"key":"3469_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655826","volume":"11","author":"Z Song","year":"2021","unstructured":"Song Z, Zhou Y, Bai X, Zhang D. A practical nomogram to predict early death in advanced epithelial ovarian cancer. Front Oncol. 2021;11: 655826.","journal-title":"Front Oncol"},{"issue":"4","key":"3469_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3469_CR8","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.21037\/tcr.2019.09.53","volume":"8","author":"S Zhou","year":"2019","unstructured":"Zhou S, Liu Y, Yin W, Liao Q, Quan Q, Mu X. Clinicopathologic factors associated with short-term survival in advanced epithelial ovarian cancer. Transl Cancer Res. 2019;8(6):2396\u2013404.","journal-title":"Transl Cancer Res"},{"key":"3469_CR9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/diagnostics11040697","volume":"11","author":"A De Leo","year":"2021","unstructured":"De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, Chiarucci F, Rosini F, Ravegnini G, Pession A, Turchetti D, Zamagni C, Perrone AM, De Iaco P, Tallini G, de Biase D. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors. Diagnostics. 2021;11:4.","journal-title":"Diagnostics"},{"issue":"24","key":"3469_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.21037\/atm-20-1422","volume":"8","author":"F Fostira","year":"2020","unstructured":"Fostira F, Papadimitriou M, Papadimitriou C. Current practices on genetic testing in ovarian cancer. Ann Transl Med. 2020;8(24):1703.","journal-title":"Ann Transl Med"},{"issue":"6","key":"3469_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127363","volume":"10","author":"F Kwiatkowski","year":"2015","unstructured":"Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon YJ. BRCA mutations increase fertility in families at hereditary breast\/ovarian cancer risk. PLoS ONE. 2015;10(6): e0127363.","journal-title":"PLoS ONE"},{"key":"3469_CR12","first-page":"15","volume":"23","author":"D Kim","year":"2022","unstructured":"Kim D, Nam HJ. PARP inhibitors: clinical limitations and recent attempts to overcome them. Int J Mol Sci. 2022;23:15.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3469_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/pcmedi\/pbaa030","volume":"3","author":"P Zhou","year":"2020","unstructured":"Zhou P, Wang J, Mishail D, Wang CY. Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med. 2020;3(3):187\u2013201.","journal-title":"Precis Clin Med"},{"issue":"8","key":"3469_CR14","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.2174\/0929867325666180201114306","volume":"26","author":"M Toma","year":"2019","unstructured":"Toma M, Skorski T, Sliwinski T. DNA double strand break repair - related synthetic lethality. Curr Med Chem. 2019;26(8):1446\u201382.","journal-title":"Curr Med Chem"},{"issue":"11","key":"3469_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","volume":"95","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866\u201371.","journal-title":"Cancer Sci"},{"issue":"1","key":"3469_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3802\/jgo.2013.24.1.83","volume":"24","author":"BA Goff","year":"2013","unstructured":"Goff BA. Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol. 2013;24(1):83\u201391.","journal-title":"J Gynecol Oncol"},{"key":"3469_CR17","doi-asserted-by":"publisher","first-page":"175883592311731","DOI":"10.1177\/17588359231173183","volume":"15","author":"H Hockings","year":"2023","unstructured":"Hockings H, Miller RE. The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol. 2023;15:17588359231173184.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3469_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12967-022-03776-y","volume":"20","author":"D Leung","year":"2022","unstructured":"Leung D, Price ZK, Lokman NA, Wang W, Goonetilleke L, Kadife E, Oehler MK, Ricciardelli C, Kannourakis G, Ahmed N. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism. J Transl Med. 2022;20(1):556.","journal-title":"J Transl Med"},{"issue":"22","key":"3469_CR19","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/cmdc.202000391","volume":"15","author":"NA Yusoh","year":"2020","unstructured":"Yusoh NA, Ahmad H, Gill MR. Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy. ChemMedChem. 2020;15(22):2121\u201335.","journal-title":"ChemMedChem"},{"issue":"11","key":"3469_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207399","volume":"13","author":"ZP Lin","year":"2018","unstructured":"Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLoS ONE. 2018;13(11): e0207399.","journal-title":"PLoS ONE"},{"key":"3469_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cancers13040669","volume":"13","author":"Y Gilad","year":"2021","unstructured":"Gilad Y, Gellerman G, Lonard DM, O\u2019Malley BW. Drug combination in cancer treatment-from cocktails to conjugated combinations. Cancers. 2021;13:4.","journal-title":"Cancers"},{"issue":"4","key":"3469_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1124\/mi.7.4.8","volume":"7","author":"LD Mayer","year":"2007","unstructured":"Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7(4):216\u201323.","journal-title":"Mol Interv"},{"issue":"22","key":"3469_CR23","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1158\/1078-0432.CCR-13-1536","volume":"19","author":"V Shah","year":"2013","unstructured":"Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193\u2013204.","journal-title":"Clin Cancer Res"},{"key":"3469_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jconrel.2016.10.014","volume":"243","author":"J Sapiezynski","year":"2016","unstructured":"Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250\u201368.","journal-title":"J Control Release"},{"issue":"36","key":"3469_CR25","doi-asserted-by":"publisher","first-page":"12962","DOI":"10.1073\/pnas.0504274102","volume":"102","author":"SS Dharap","year":"2005","unstructured":"Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102(36):12962\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3469_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5): e09394.","journal-title":"Heliyon"},{"key":"3469_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.supflu.2020.104984","volume":"165","author":"L Maja","year":"2020","unstructured":"Maja L, \u017deljko K, Mateja P. Sustainable technologies for liposome preparation. J Supercritic Fluids. 2020;165: 104984.","journal-title":"J Supercritic Fluids"},{"issue":"1","key":"3469_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"3469_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2217\/nnm.11.131","volume":"7","author":"M Zhang","year":"2012","unstructured":"Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine (Lond). 2012;7(2):185\u201397.","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"3469_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9\u201316.","journal-title":"Br J Cancer"},{"key":"3469_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pharmaceutics12100939","volume":"12","author":"P Skupin-Mrugalska","year":"2020","unstructured":"Skupin-Mrugalska P, Minko T. Development of liposomal vesicles for osimertinib Delivery to EGFR mutation-positive lung cancer cells. Pharmaceutics. 2020;12:10.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3469_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263\u201371.","journal-title":"AAPS J"},{"key":"3469_CR33","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1038\/ncomms8419","volume":"6","author":"TA Ince","year":"2015","unstructured":"Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun. 2015;6:7419.","journal-title":"Nat Commun"},{"issue":"4","key":"3469_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/cells10040867","volume":"10","author":"A Romaniuk-Drapa\u0142a","year":"2021","unstructured":"Romaniuk-Drapa\u0142a A, Toto\u0144 E, Konieczna N, Machnik M, Barczak W, Kowal D, Kopczy\u0144ski P, Kaczmarek M, Rubi\u015b B. hTERT downregulation attenuates resistance to DOX, Impairs FAK-mediated adhesion, and leads to autophagy induction in breast cancer cells. Cells. 2021;10(4):867.","journal-title":"Cells"},{"key":"3469_CR35","unstructured":"Strategies to Modify the Drug Release from Pharmaceutical Systems: Woodhead Publishing; 2015."},{"issue":"6","key":"3469_CR36","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1074\/jbc.M111.296475","volume":"287","author":"AG Patel","year":"2012","unstructured":"Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem. 2012;287(6):4198\u2013210.","journal-title":"J Biol Chem"},{"issue":"7","key":"3469_CR37","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1021\/cr900097c","volume":"109","author":"Y Pommier","year":"2009","unstructured":"Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009;109(7):2894\u2013902.","journal-title":"Chem Rev"},{"issue":"10","key":"3469_CR38","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"3469_CR39","first-page":"294","volume":"41","author":"TT Chang","year":"2000","unstructured":"Chang TT, Chou TC. Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan. 2000;41(6):294\u2013302.","journal-title":"Acta Paediatr Taiwan"},{"key":"3469_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399.","journal-title":"Int J Womens Health"},{"key":"3469_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers14122885","volume":"14","author":"JM Liberto","year":"2022","unstructured":"Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR. Current and emerging methods for ovarian cancer screening and diagnostics: a comprehensive review. Cancers. 2022;14:12.","journal-title":"Cancers"},{"key":"3469_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/jcm8040435","volume":"8","author":"MYT Keung","year":"2019","unstructured":"Keung MYT, Wu Y, Vadgama JV. PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. J Clin Med. 2019;8:4.","journal-title":"J Clin Med"},{"issue":"3","key":"3469_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/annonc\/mdw697","volume":"28","author":"UA Matulonis","year":"2017","unstructured":"Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol. 2017;28(3):443\u20137.","journal-title":"Ann Oncol"},{"key":"3469_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte D, Vale N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022;3: 100110.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"3","key":"3469_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1124\/jpet.114.222448","volume":"353","author":"Y Shen","year":"2015","unstructured":"Shen Y, Aoyagi-Scharber M, Wang B. Trapping PARP. J Pharmacol Exp Ther. 2015;353(3):446\u201357.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3469_CR46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/jpet.113.210146","volume":"349","author":"J Murai","year":"2014","unstructured":"Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther. 2014;349(3):408\u201316.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3469_CR47","doi-asserted-by":"publisher","DOI":"10.20883\/medical.e761","volume":"91","author":"D \u0141a\u017cewski","year":"2022","unstructured":"\u0141a\u017cewski D, Murias M, Wierzchowski M. Pegylation \u2013 in search of balance and enhanced bioavailability. JMS. 2022;91(4): e761.","journal-title":"JMS"},{"issue":"11","key":"3469_CR48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207\u201314.","journal-title":"Lancet Oncol"},{"key":"3469_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1126\/scitranslmed.aav4508","volume":"11","author":"AR Kaplan","year":"2019","unstructured":"Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51. Sci Transl Med. 2019;11:492.","journal-title":"Sci Transl Med."},{"issue":"25","key":"3469_CR50","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, Fujiwara K, Vergote I, Colombo N, M\u00e4enp\u00e4\u00e4 J, Selle F, Sehouli J, Lorusso D, Guerra Al\u00eda EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marm\u00e9 F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. Olaparib plus Bevacizumab as First-Line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"key":"3469_CR51","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","volume":"15","author":"G Freyer","year":"2024","unstructured":"Freyer G, Floquet A, Tredan O, et al. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nat Commun. 2024;15:1985.","journal-title":"Nat Commun"},{"issue":"16","key":"3469_CR52","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26(16):4268\u201379.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3469_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","volume":"30","author":"Y Drew","year":"2024","unstructured":"Drew Y, Kim JW, Penson RT, O\u2019Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S. MEDIOLA investigators olaparib plus durvalumab, with or without bevacizumab, as treatment in parp inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study. Clin Cancer Res. 2024;30(1):50\u201362.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3469_CR54","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","volume":"30","author":"J Samol","year":"2012","unstructured":"Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2012;30(4):1493\u2013500.","journal-title":"Invest New Drugs"},{"key":"3469_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy285.208","author":"WAE Hendrickson","year":"2018","unstructured":"Hendrickson WAE, Costello B, Jewell A, Kennedy V, Fleming G, Corr B, Taylor SE, Lea J, Reid J, Swisher E, Satele D, Allred J, Lensing J, Ivy SP, Erlichman C, Adjei AA, Kaufmann S. A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer. Annal Oncol. 2018. https:\/\/doi.org\/10.1093\/annonc\/mdy285.208.","journal-title":"Annal Oncol"},{"issue":"4","key":"3469_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100212","volume":"6","author":"JA Perez-Fidalgo","year":"2021","unstructured":"Perez-Fidalgo JA, Cortes A, Guerra E, Garcia Y, Iglesias M, Bohn Sarmiento U, Calvo Garcia E, Manso Sanchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, Gonzalez-Martin A. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO Open. 2021;6(4): 100212.","journal-title":"ESMO Open"},{"key":"3469_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/life13091878","volume":"13","author":"Y Pan","year":"2023","unstructured":"Pan Y, Ren H, Lan L, Li Y, Huang T. Review of predicting synergistic drug combinations. Life. 2023;13:9.","journal-title":"Life"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-024-03469-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:03:43Z","timestamp":1723475023000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-024-03469-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1186\/s12935-024-03469-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"It is not applicable as no humans were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}